Jun. 5 at 12:13 AM
$ARDX Surely longtime ARDX holders remember our previous Chief Commercial Officer , Susan Rodriguez, who did an amazing job with the launch of Xphoza and IBSRELA . After she left
$ARDX (reasons still confound me as she was outstanding) she join Avadel Pharma as Chief Operating Officer which was subsequently acquired by Alkermes . Now she has a new role as Chief Commercial and Strategy Officer at Monopar Therapeutics
$MNPR pre-commericial stage company .
The Company remains on track with its plans to submit the New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in mid-2026. Susan Rodriguez, the Company’s Chief Commercial and Strategy Officer who joined in March 2026, is leading commercial readiness activities in preparation for a potential launch.
I'm betting on Suzan again .
